BioTech/Drugs - , N/A, US
We are a leader in developing a hemoglobin-based oxygen-carrying red blood cell substitute. The initial indication we are seeking for our product PolyHeme® is the treatment of life-threatening hemoglobin levels when blood transfusion is indicated but red blood cells may not be available, appropriate or acceptable. PolyHeme® is a solution of chemically modified human hemoglobin that requires no cross-matching and is therefore compatible with all blood types. It has an extended shelf life in excess of 12 months.